Medical Management of Gastroesophageal Reflux Disease

Gastroenterology Clinics of North America

Volumn 37, Issue 4, 2008, Pages 879-899

  Wang, Changcheng ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Antireflux surgery; Antisecretory therapy; Gastroesophageal reflux disease (GERD); Proton pump inhibitors (PPIs)

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; AGN 201 904 Z; ALGINIC ACID; ANTACID AGENT; BACLOFEN; BENATOPRAZOLE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; SEROTONIN 4 AGONIST; STOMACH SECRETION INHIBITOR; TAK 390 MR; TEGASEROD; UNCLASSIFIED DRUG; XP 19986;

ADD ON THERAPY; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; BEDTIME DOSAGE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED DRUG RELEASE; COUGHING; DELAYED DRUG RELEASE; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOSCOPIC SURGERY; ESOPHAGITIS; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; GASTRONTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MORNING DOSAGE; NON EROSIVE REFLUX DISEASE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PLASMA HALF LIFE; REFLUX ESOPHAGITIS; REVIEW; SLEEP DISORDER; SUPRAESOPHAGEAL REFLUX DISEASE;

GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 56349147425     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2008.09.001     Document Type: Review

References (130)

1. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 41 (2007) 131-137
2. Dent J., El-Serag H.B., Wallander M.A., et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54 (2005) 710-717
3. Fock K.M., Talley N.J., Fass R., et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 23 1 (2008) 8-22
4. Vakil N., van Zanten S.V., Kahrilas P., et al. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101 8 (2006) 1900-1920
5. Galmiche J.P., Clouse R.E., Bálint A., et al. Functional esophageal disorders. Gastroenterology 130 5 (2006) 1459-1465
6. Fass R., and Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 51 6 (2002) 885-892
7. Bruley Des Varannes S., Marek L., Humeau B., et al. Gastroesophageal reflux disease in primary care: prevalence, epidemiology and quality of life of patients. Gastroenterol Clin Biol 30 (2006) 364-370
8. Labenz J., Jaspersen D., Kulig M., et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 99 (2004) 1652-1656
9. Barlow W.J., and Orlando R.C. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 128 3 (2005) 771-778
10. Caviglia R., Ribolsi M., Maggiano N., et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 100 (2005) 543-548
11. Lind T., Havelund T., Carlsson R., et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32 10 (1997) 974-979
12. Wang C., and Hunt R.H. Precise role of acid in nonerosive reflux disease (NERD). Digestion 78 Suppl 1 (2008) 31-41
13. Peghini P.L., Katz P.O., Bracy N.A., et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93 (1998) 763-767
14. Tutuian R., Katz P.O., and Castell D.O. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 16 (2004) 441-443
15. Katz P.O. Review article: putting immediate-release proton-pump inhibitors into clinical practice. Improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther 22 Suppl 3 (2005) 31-38
16. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122 (2002) 625-632
17. Robertson D., Aldersley M., Shepherd H., et al. Patterns of acid reflux in complicated oesophagitis. Gut 28 (1987) 1484-1488
18. Campos G.M., Peters J.H., DeMeester T.R., et al. The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease. Arch Surg 134 (1999) 882-887
19. Orr W.C. Nighttime gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 17 (2005) 113-120
20. Dean B.B., Crawley J.A., Schmitt C.M., et al. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 17 (2003) 1309-1317
21. Katz P.O., Castell D.O., Chen Y., et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 20 4 (2004) 399-406
22. Chey W.D., Mody R., Chen L., et al. Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs). Gastroenterology 134 4 Suppl 1 (2008) A323-A324
23. Shaker R., Castell D.O., Schoenfeld P.S., et al. Nighttime heartburn is an underappreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 98 7 (2003) 1487-1493
24. Hunt R.H., Yuan Y., and Mohammad Y. GERD: new strategies and new failures. J Clin Gastroenterol 41 Suppl 2 (2007) S72-S80
25. Holtmann G., Hunt R.H., Katelaris P., et al. What is the truth? Sleep disturbance as assessed by investigators or a validated instrument (ReQuestTM) in patients with GERD. Am J Gastroenterol 102 Suppl 2 (2007) S124-S125
26. Holtmann G., Doerfler H., Hunt R.H., et al. What is the truth? Sleep disturbance as assessed by investigators or a validated instrument (Request) in patients with gastro-oesophageal reflux disease (GERD). Gut 56 UEGW Suppl (2007) G114
27. Ing A.J., Ngu M.C., and Breslin A.B. Obstructive sleep apnea and gastroesophageal reflux. Am J Med 108 Suppl 4A (2000) 120S-125S
28. Orr W.C., Heading R., Johnson L.F., et al. Review article: sleep and its relationship to gastro-oesophageal reflux. Aliment Pharmacol Ther 20 Suppl 9 (2004) 39-46
29. Galmiche J.P., Zerbib F., and Bruley des Varannes S. Review article: respiratory manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 27 6 (2008) 449-464
30. Qadeer M.A., Phillips C.O., Lopez A.R., et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 11 (2006) 2646-2654
31. Gatta L., Vaira D., Sorrenti G., et al. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther 25 4 (2007) 385-392
32. Chang A.B., Lasserson T.J., Gaffney J., et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 4 (2006) CD004823
33. El-Serag H.B., Lee P., Buchner A., et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 96 4 (2001) 979-983
34. Langevin S., and Hanh N. GERD-induced ENT symptoms: a prospective placebo-controlled study with omeprazole 40 mg a day. Gastroenterology 120 (2001) A-16
35. Steward D.L., Wilson K.M., Kelly D.H., et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 131 4 (2004) 342-350
36. Dent J., Brun J., Fendrick A.M., et al. An evidence-based appraisal of reflux disease management: the Genval workshop report. Gut 44 (1999) S1-S16
37. Ismail-Beigi F., Horton P.F., and Pope C.E. Histological consequences of gastroesophageal reflux in man. Gastroenterology 58 (1970) 163-174
38. Ismail-Beigi F., and Pope C.E. Distribution of the histological changes of gastroesophageal reflux disease in the distal esophagus of man. Gastroenterology 66 (1974) 1109-1113
39. Nakamura T., Shirakawa K., Masuyama H., et al. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 21 Suppl 2 (2005) 19-26
40. Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 41 (2006) 95-99
41. Kiesslich R., Kanzler S., Vieth M., et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis 22 2 (2004) 221-227
42. Zentilin P., Savarino V., Mastracci L., et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 100 10 (2005) 2299-2306
43. Caviglia R., Ribolsi M., Gentile M., et al. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 25 (2007) 629-636
44. Vieth M., Fiocca R., Haringsma J., et al. Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesions. Dig Dis 22 (2004) 208-212
45. Vieth M., Kulig M., Leodolter A., et al. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther 23 2 (2006) 313-319
46. Calabrese C., Bortolotti M., Fabbri A., et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 100 3 (2005) 537-542
47. Johnson L.F., and DeMeester T.R. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1 Suppl 8 (1986) 52-58
48. Wise J.L., and Murray J.A. Utilising multichannel intraluminal impedance for diagnosing GERD: a review. Dis Esophagus 20 2 (2007) 83-88
49. Sifrim D., Castell D., Dent J., et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 53 7 (2004) 1024-1031
50. Zerbib F., Roman S., Ropert A., et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 101 9 (2006) 1956-1963
51. Katz P.O. Medical therapy for gastroesophageal reflux disease in 2007. Rev Gastroenterol Disord 7 4 (2007) 193-203
52. DeVault K.R., and Castell D.O. American College of Gastroenterology: updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 1 (2005) 190-200
53. Bell N.J., Burget D., Howden C.W., et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 Suppl 1 (1992) 59-67
54. Hunt R.H. Importance of pH control in the management of GERD. Arch Intern Med 159 7 (1999) 649-657
55. Katz P.O., Ginsberg G.G., Hoyle P.E., et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 25 5 (2007) 617-628
56. Tytgat G.N., McColl K., Tack J., et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 27 3 (2008) 249-256
57. Tytgat G.N., and Simoneau G. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension. Aliment Pharmacol Ther 23 6 (2006) 759-765
58. Tran T., Lowry A.M., and El-Serag H.B. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther 25 2 (2007) 143-153
59. Tytgat G.N., Heading R.C., Müller-Lissner S., et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 18 3 (2003) 291-301
60. Inadomi J.M., and Fendrick A.M. PPI use in the OTC era: who to treat, with what, and for how long?. Clin Gastroenterol Hepatol 3 3 (2005) 208-215
61. Fendrick A.M., Shaw M., Schachtel B., et al. Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol 2 1 (2004) 17-21
62. DeVault K.R., and Castell D.O. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease: Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 155 20 (1995) 2165-2173
63. Behar J., Brand D.L., Brown F.C., et al. Cimetidine in the treatment of symptomatic gastroesophageal reflux: a double-blind controlled trial. Gastroenterology 74 2 Pt 2 (1978) 441-448
64. Sontag S., Robinson M., McCallum R.W., et al. Ranitidine therapy for gastroesophageal reflux disease: results of a large double-blind trial. Arch Intern Med 147 8 (1987) 1485-1491
65. Euler A.R., Murdock Jr. R.H., Wilson T.H., et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 88 4 (1993) 520-524
66. Khan M., Santana J., Donnellan C., et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2 (2007) CD003244
67. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 3 (2006) CD002095
68. Yaghoobi M., Thabane M., and Hunt R.H. Response to proton pump inhibitor (PPI) therapy in different grades of erosive esophagitis. Gastroenterology 132 4 Suppl 2 (2007) A-490(T1208)
69. Devault K.R., Morgenstern D.M., Lynn R.B., et al. Effect of pantoprazole in older patients with erosive esophagitis. Dis Esophagus 20 (2007) 411-415
70. Richter J.E., and Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 95 (2000) 3071-3080
71. Sharma V.K., Leontiadis G.I., and Howden C.W. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 15 (2001) 227-231
72. Gralnek I.M., Dulai G.S., Fennerty M.B., et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 4 12 (2006) 1452-1458
73. Dean B.B., Gano Jr. A.D., Knight K., et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2 (2004) 656-664
74. Edwards S.J., Lind T., and Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis-a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 24 5 (2006) 743-750
75. Yaghoobi M, Padol S, Yuan Y, et al. Impact of esophagitis classification in evaluating healing of erosive esophagitis after therapy with proton pump inhibitors: a pooled analysis. (2007; manuscript submitted).
76. Yaghoobi M., and Hunt R.H. Placebo effect in the treatment of gastroesophageal reflux disease (GERD): consideration for objective and subjective endpoints in proton pump inhibitor (PPI) trials. Gastroenterology 132 4 Suppl 2 (2007) A-487 (T1195)
77. Richter J.E., Campbell D.R., Kahrilas P.J., et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 160 (2000) 1803-1809
78. Shapiro M., Green C., Faybush E.M., et al. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther 23 (2006) 321-329
79. Martinez S.D., Malagon I.B., Garewal H.S., et al. Non-erosive reflux disease (NERD): acid reflux and symptom patterns. Aliment Pharmacol Ther 17 4 (2003) 537-545
80. Gerson L.B., Boparai V., Ullah N., et al. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 20 6 (2004) 637-643
81. Wani S., Sampliner R.E., Weston A.P., et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. Aliment Pharmacol Ther 22 7 (2005) 627-633
82. Lanas A. Potent gastric acid inhibition in the management of Barrett's oesophagus. Drugs 65 Suppl 1 (2005) 75-82
83. Hillman L.C., Chiragakis L., Shadbolt B., et al. Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180 8 (2004) 387-391
84. Hillman L.C., Chiragakis L., Shadbolt B., et al. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 27 4 (2008) 321-326
85. El-Serag H.B., Aguirre T.V., Davis S., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99 10 (2004) 1877-1883
86. Donnellan C., Sharma N., Preston C., et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2 (2005) CD003245
87. Modlin I.M., and Moss S.F. Symptom evaluation in gastroesophageal reflux disease. J Clin Gastroenterol 42 5 (2008) 558-563
88. Pace F., Tonini M., Pallotta S., et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther 26 2 (2007) 195-204
89. Metz D.C., Inadomi J.M., Howden C.W., et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 102 3 (2007) 642-653
90. Fass R. Proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 67 11 (2007) 1521-1530
91. Delhotal-Landes B., Cournot A., Vermerie N., et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet Spec No 3 (1991) 315-320
92. Hatlebakk J.G., Katz P.O., Camacho-Lobato L., et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 14 10 (2000) 1267-1272
93. Katz P.O., Scheiman J.M., and Barkun A.N. Review article: acid-related disease-what are the unmet clinical needs?. Aliment Pharmacol Ther 23 Suppl 2 (2006) 9-22
94. Peghini P.L., Katz P.O., and Castell D.O. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115 6 (1998) 1335-1339
95. Rackoff A., Agrawal A., Hila A., et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 18 6 (2005) 370-373
96. Ours T.M., Fackler W.K., Richter J.E., et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 98 3 (2003) 545-550
97. Fass R., Shapiro M., Dekel R., et al. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease-where next?. Aliment Pharmacol Ther 22 2 (2005) 79-94
98. Coron E., Hatlebakk J.G., and Galmiche J.P. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol 23 4 (2007) 434-439
99. Richter J.E. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 4 12 (2007) 658-664
100. Charbel S., Khandwala F., and Vaezi M.F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 100 2 (2005) 283-289
101. Mainie I., Tutuian R., Shay S., et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55 10 (2006) 1398-1402
102. Triadafilopoulos G. Endotherapy and surgery for GERD. J Clin Gastroenterol 41 Suppl 2 (2007) S87-S96
103. Zaninotto G., Portale G., Costantini M., et al. Long-term results (6-10 years) of laparoscopic fundoplication. J Gastrointest Surg 11 9 (2007) 1138-1145
104. Anvari M., and Allen C. Five-year comprehensive outcomes evaluation in 181 patients after laparoscopic Nissen fundoplication. J Am Coll Surg 196 1 (2003) 51-57 [discussion: 57-8]
105. Wijnhoven B.P., Lally C.J., Kelly J.J., et al. Use of antireflux medication after antireflux surgery. J Gastrointest Surg 12 3 (2008) 510-517
106. Bonatti H., Bammer T., Achem S.R., et al. Use of acid suppressive medications after laparoscopic antireflux surgery: prevalence and clinical indications. Dig Dis Sci 52 1 (2007) 267-272
107. Castell D., Bagin R., Goldlust B., et al. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther 21 12 (2005) 1467-1474
108. Katz P.O., Koch F.K., Ballard E.D., et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 25 2 (2007) 197-205
109. Zhang W., Wu J.-T., and Atkinson S. Pharmacokinetic (PK), pharmacodynamic (PD), and safety evaluation of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole (LAN) in healthy subjects. Gastroenterology 132 4 Suppl 2 (2007) A-487
110. Sharma P., Shaheen N.J., Perez M.C., et al. TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis (EE): data from two randomized controlled trials. Gastroenterology 134 4 Suppl 1 (2008) A-171
111. Metz D.C., Howden C.W., Perez M.C., et al. TAK-390MR, a proton pump inhibitor with a novel dual delayed release formulation, maintains healing and controls heartburn in GERD patients with healed erosive esophagitis. Gastroenterology 134 4 Suppl 1 (2008) A-171
112. Milkes D., Gerson L.B., and Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 99 (2004) 991-996
113. Hunt R.H. Review article: the unmet needs in delayed-release proton pump inhibitor therapy in 2005. Aliment Pharmacol Ther 22 Suppl 3 (2005) 10-19
114. Shin J.M., Homerin M., Domagala F., et al. Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K+ -ATPase in vitro and in vivo. Biochem Pharmacol 71 6 (2006) 837-849
115. Galmiche J.P., Bruley Des Varannes S., Ducrotte P., et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 19 (2004) 655-662
116. Yuan Y., Chen Y., Hunt R.H., et al. Dose-effect of S-tenatoprazole-Na in healthy volunteers: a meta-analysis of individual subject data from four pharmacodynamic studies. Gastroenterology 134 4 Suppl 1 (2008) A176 (S1093)
117. Hunt R.H., Armstrong D., and Yaghoobi M. S-Tenatoprazole-Na 30 mg, 60 mg and 90 mg versus esomeprazole (Eso) 40 mg in healthy male volunteers (HMVS). Gastroenterology 132 4 Suppl 2 (2007) A-488-9
118. Thomson A.B., Cohen P., Ficheux H., et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther 23 (2006) 1179-1187
119. Hunt R.H., Armstrong D., and Yaghoobi M. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 28 (2008) 187-199
120. +-ATPase. Biochem Pharmacol 73 2 (2007) 198-205
121. +-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 291 (2006) G838-G843
122. Kahrilas P.J., Dent J., Lauritsen K., et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 5 12 (2007) 1385-1391
123. Dent J., Kahrilas P.J., Hatlebakk J., et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 103 1 (2008) 20-26
124. Koek G.H., Sifrim D., Lerut T., et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52 (2003) 1397-1402
125. Ciccaglione A.F., and Marzio L. Effect of acute and chronic administration of the GABA-B agonist baclofen on 24-hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 52 (2003) 464-470
126. Vela M.F., Tutuian R., Katz P.O., et al. Baclofen decreases acid and non-acid postprandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 17 (2003) 243-251
127. Castell D.O., Gerson L.B., Hirota W.K., et al. R-Baclofen prodrug XP19986 decrease reflux episodes and is well tolerated in GERD patients. Gastroenterology 132 4 Suppl 2 (2007) A-486
128. Rodriguez-Stanley S., Zubaidi S., Proskin H.M., et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 4 4 (2006) 442-450
129. Kahrilas P.J., Quigley E.M., Castell D.O., et al. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14 11 (2000) 1503-1509
130. Tutuian R., Mainie I., Allan R., et al. Effects of a 5-HT (4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 24 1 (2006) 155-162